Biotech Fury
Titoli biotech rischiosi ma potenzialmente esplosivi nei prossimi 6 mesi. Per duri e puri :)
Tools I Use
Real-Time Market Scanner
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Recommended Platform
Professional Trading Workflow
Charts • Watchlists • Multi-broker tools
Built for active traders
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Category Archives
Category for old articles
Cruises Report
Comparative Cruise Lines report
Airlines Report
Comparative report Major Airlines
QH stock
QH | QUHUO LIMITED
+26% WEEKLY SPIKE - EXTREME MICRO-CA
$SPRU stock
Intraday move
ABEO stock
ABEO Daily Catalyst Report | Merlintrader ?? ?? Daily Catalyst Analysis ABEO | ABEONA THERAPEUTICS +28-33% SPIKE – GENE THERAPY COMMERCIAL LAUNCH INFLECTION November 12, 2025 | Q3 Earnings + FDA J-Code Catalyst Analysis Daily Catalyst Analysis ABEO | ABEONA…
LPTX stock
LPTX → CYPH | CYPHERPUNK TECHNOLOGIES
BIOTECH TO CRYPTO PIVOT - TICKER CHANGES TOMORROW
$ONDS stock
BULLISH CASE: +426% revenue growth YoY (Wasp drone orders), strategic acquisitions (Sentrycs Nov 4, Safe Pro Nov 6), defense sector tailwinds, 500 units Wasp scalable a 20,000/month, analyst consensus Strong Buy, PT $7.25
$SWAG stock
Earnings tomorrow Nov 13
$VCIG stock
Intraday move
$BKYI stock
Intraday move
$CMCT stock
Intraday Move
$LUCY stock
Innovative Eyewear Inc. - Smart Glasses Company - Earnings Release Today
$FUFU stock
Intraday Move
$AMZE stock
Intraday move
$SLRX stock
Intraday alert
PDUFA dates jan 2026
Comprehensive Biotech Approval Timeline - January 2026
BIOTECH e non solo
âš¡ CATALIZZATORI 60 GIORNI | "La Finestra si Apre"
Novembre - Dicembre 2025 è il mese critico. Decisioni FDA per AUTL (domani), AGIO (7 dic), MIST (13 dic). Approvazioni SEC Solana/XRP dicembre. Earnings tech late dicembre. Tre mesi di volatilità esplosiva. Report strategico con allocazione, stop-loss, profit-taking. Griglie complete: prezzi attuali vs target long/bear.
$AUTL
AUTL Rischio alto ricompensa alta; da prendere a piccole dosi potrebbe essere una sorpresa.
$AGIO
Agios Pharmaceuticals è un biotech specializzato nel trattamento di rare malattie ematologiche attraverso l'attivazione della piruvato chinasi. Il suo principale asset PYRUKYND (mitapivat) rappresenta una breakthrough therapy per thalassemia e sickle cell disease, con catalizzatori critici imminenti nel Q4 2025.